Unveiling a BRAF Signature Proficient in Accurately Capturing Oncogenic Activity and Guiding Prognostic Prediction Across Multiple Cancers.

ABSTRACT: Although BRAF is frequently mutated across multiple cancer types, its clinical utility as a prognostic biomarker has remained inconsistent in clinical practice, likely due to additional events modulating BRAF signaling pathways. This inconsistency has driven our investigation into the broader landscape of BRAF signaling and the development of a robust molecular signature to assess BRAF-driven oncogenic activity. To achieve this, we introduced BRAF25, a transcriptional signature designed to effectively capture BRAF oncogenic activity. Our findings reveal that 25.6% of TCGA colorectal cancer (CRC) tumors exhibit BRAF pathway activation, even in 19.4% of BRAF wild-type (WT) cases, suggesting alternative mechanisms driving pathway activation. The BRAF-active subtype, termed BAG-3 (BRAF

SUBMITTER: Yang K 

PROVIDER: S-EPMC12868921 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature